Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Brief Summary: The purpose of this study is to compare the clinical benefit, as measured by overall survival, of nivolumab with that of. dacarbazine in patients with previously untreated, unresectable, or metastatic melanoma


Options:
A: Arm Label: Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Placebo for Nivolumab, Biological: Placebo for Ipilimumab | Arm Label: Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Biological: Placebo for Nivolumab | Arm Label: Arm C: Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab
B: Arm Label: Nivolumab, 3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (Nivolumab), Drug: Placebo matching Dacarbazine | Arm Label: Dacarbazine, 1000 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo matching BMS-936558 (Nivolumab), Drug: Dacarbazine | Intervention Type: BIOLOGICAL; Name: BMS-936558 (Nivolumab); Assigned to Arm(s): Nivolumab, 3 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo matching BMS-936558 (Nivolumab); Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Placebo matching Dacarbazine; Assigned to Arm(s): Nivolumab, 3 mg/kg
C: Arm Label: Surgery; Type: OTHER; Interventions: Procedure: Immediate surgical resection of melanoma lesion(s) | Arm Label: Talimogene Laherparepvec; Type: EXPERIMENTAL; Interventions: Drug: Talimogene Laherparepvec | Intervention Type: DRUG; Name: Talimogene Laherparepvec; Assigned to Arm(s): Talimogene Laherparepvec | Intervention Type: PROCEDURE; Name: Immediate surgical resection of melanoma lesion(s); Assigned to Arm(s): Surgery
D: Arm Label: Arm I (aldesleukin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: gp100 Antigen, Drug: Montanide ISA 51 VG, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Other: Laboratory Biomarker Analysis | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: BIOLOGICAL; Name: gp100 Antigen; Assigned to Arm(s): Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: DRUG; Name: Montanide ISA 51 VG; Assigned to Arm(s): Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)

Answer: B